NCT03387163View on ClinicalTrials.gov

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

CompletedOBSERVATIONAL
Enrollment

402

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

June 21, 2019

Study Completion Date

June 21, 2019

Conditions
Heart Failure, Systolic
Interventions
DRUG

Sacubitril/Valsartan

commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103

Trial Locations (1)

10029

Novartis Investigative Site, New York

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY